Samil Pharmaceutical (000520) Fundamentals 2026 — Revenue Analysis | SniperIQ
Samil Pharmaceutical (000520) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩134.0B, trading at ₩6270.00 on the KSC. This SniperIQ fundamentals page covers Samil Pharmaceutical's valuation, profitability (net margin -17.3%), revenue (₩210.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Samil Pharmaceutical's market cap?
Samil Pharmaceutical (000520) has a market capitalization of approximately ₩134.0B, trading at ₩6270.00 on the KSC. Market cap moves with the live share price.
What is Samil Pharmaceutical's P/E ratio?
Samil Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Samil Pharmaceutical?
Samil Pharmaceutical runs a net profit margin of -17.3%, a gross margin of 33.6%, and an operating margin of -12.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Samil Pharmaceutical generate?
Samil Pharmaceutical reported revenue of ₩210.4B for fiscal year 2025, with net income of -₩34.6B and earnings per share (EPS) of -1627.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Samil Pharmaceutical pay a dividend?
Samil Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Samil Pharmaceutical financially healthy?
Samil Pharmaceutical carries a debt-to-equity ratio of 1.29x and a current ratio of 0.46x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Samil Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Samil Pharmaceutical (000520) the key facts are: market cap ₩134.0B, revenue ₩210.4B, 52-week range 5500-12860. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Samil Pharmaceutical's full fundamentals live
Get Samil Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.